BMO Capital downgraded Verve Therapeutics (VERV) to Market Perform from Outperform with a $13.50 price target. Verve was downgraded to reflect Eli Lilly’s (LLY) definitive agreement to acquire Verve for up to $1.3B. BMO expects a “smooth” deal closure by Q3 of 2025 given the two companies’ extensive relationship/partnership.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV:
- Crispr posts strong CTX310 data, says Chardan
- Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition
- SanDisk initiated, Analog Devices upgraded: Wall Street’s top analyst calls
- Hold Rating on Verve Therapeutics Acquisition by Eli Lilly: Fair Valuation with Low Competing Bid Potential
- Verve Therapeutics downgraded to Neutral from Buy at H.C. Wainwright